Phase 3Recruiting
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 300 planned
- Conditions
- Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Enicepatide; Placebo
- Ages
- adults, older adults
- Registry
- NCT07670416
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.
Primary outcomes
- Percent Change From Baseline in Body Weight at Week 52
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered